1037834-87-9

Basic information

• Product Name: 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2h-tetrazol-5-yl)-1h-benzo[d]imidazol-2(3h)-one
• CAS NO: 1037834-87-9
• Molecular Weight: 437.889
• Mol File: 1037834-87-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2h-tetrazol-5-yl)-1h-benzo[d]imidazol-2(3h)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2h-tetrazol-5-yl)-1h-benzo[d]imidazol-2(3h)-one(1037834-87-9)
• EPA Substance Registry System: 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2h-tetrazol-5-yl)-1h-benzo[d]imidazol-2(3h)-one(1037834-87-9)

Safety Data

• Hazardous Substances Data: 1037834-87-9(Hazardous Substances Data)

Usage

Description

1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2h-tetrazol-5-yl)-1h-benzo[d]imidazol-2(3h)-one, also known as PMZ-105, is a novel chemical compound with potential pharmaceutical applications. It is characterized by the presence of a piperidine ring, a tetrazole group, and a benzimidazolone moiety. PMZ-105 has demonstrated promising activity in preclinical studies, particularly in its ability to modulate neurotransmitter systems and inhibit tumor growth. Further research is being conducted to explore its potential therapeutic uses.

Uses

Used in Pharmaceutical Applications:
PMZ-105 is used as a drug candidate for various conditions, including neurological disorders and cancer, due to its ability to modulate neurotransmitter systems and inhibit tumor growth.
Used in Neurological Applications:
In the field of neurology, PMZ-105 is used as a potential treatment for neurological disorders, leveraging its neurotransmitter modulating properties to address the underlying causes of these conditions.
Used in Oncology:
In oncology, PMZ-105 is used as a potential anticancer agent, with its tumor growth inhibition capabilities being investigated for their potential to combat various types of cancer.
Used in Drug Development:
PMZ-105 is also used in the development of new drugs, as researchers explore its potential therapeutic applications and optimize its properties for maximum efficacy and safety in treating specific conditions.

Upstream product

• 320406-86-8 tert-butyl 4-((2-amino-4-cyanophenyl)amino)piperidine-1-carboxylate 
• 320406-05-1 tert-butyl 4-((4-cyano-2-nitrophenyl)amino)piperidine-1-carboxylate 
• 320407-71-4 tert-butyl 4-(5-cyano-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 
• 1009-35-4 4-fluoro-3-nitrobenzonitrile 
• 1037834-86-8 tert-butyl 4-[2-oxo-5-(1H-tetrazol-5-yl)-2,3-dihydro-1H-benzimidazol-1-yl]piperidine-1-carboxylate 
• 536-38-9 4-chlorobenzoylmethyl bromide 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 

Downstream Products

• 1037834-88-0 1-{1-[2-(4-chlorophenyl)-2-hydroxyethyl]piperidin-4-yl}-5-(1H-tetrazol-5-yl)-1,3-dihydro-2H-benzimidazol-2-one 

Relevant articles and documents

INHIBITORS OF SERINE PALMITOYLTRANSFERASE

This invention provides compounds of the formula (I) useful in the inhibition or modulation of serine palmitoyl transferase and their use in methods of treatment or amelioration of type 2 diabetes, type 1 diabetes, insulin resistance, the effects of obesity, metabolic syndrome (sometimes referred to as Syndrome X), impaired glucose tolerance, Cushing's disease, cardiovascular disease, prothrombotic conditions, myocardial infarction, hypertension, congestive heart failure, cardiomyopathy, atherosclerosis, dyslipidemia, sepsis, liver damage, retinal degenerative disorders, cachexia, emphysema, hepatitis C infections, HIV infections and inflammatory disorders and useful in methods for raising HDL plasma levels in a mammal. The compounds of this invention can also be used to prevent damage or loss of pancreatic islet beta cells (such as in the case of pancreatic beta cell apoptosis, including those related to insulin-dependent diabetes mellitus).